Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor‐Alpha Inhibitor and History of Uveitis: A Nationwide Population‐Based Study

Abstract

Background: We evaluated the risk of acute anterior uveitis (AAU) in patients with anky-losing spondylitis (AS) during treatment with tumor necrosis factor‐alpha inhibitors (TNFis). Meth-ods: This study was performed on AS patients using the Korean National Health Insurance claims database. We analyzed the first and total occurrence of AAU during the first 2 years of TNFis use according to the type of TNFis. Additionally, the occurrence of AAU was assessed in subgroups with or without prior AAU before TNFis initiation. Results: In total, 5938 AS patients initiated TNFis use between 2009 and 2017 and used them for more than 2 years. Among them, 1488 (25.1%) patients had a history of AAU before starting TNFis treatment. Compared to adalimumab, the use of etaner-cept (hazard ratio [HR] 1.77) increased the risk of AAU. The incidence rate ratio (IRR) of AAU with etanercept was significantly higher than that of adalimumab (IRR 1.78). The IRR of AAU was also higher for etanercept than adalimumab use in patients with (IRR 1.86) and without (IRR 2.92) a history of AAU. Conclusion: These data suggest that compared to anti‐TNF‐alpha monoclonal an-tibodies, etanercept has a higher incidence of AAU regardless of a history of AAU.